Revenue - Additional Information (Detail) - USD ($)			1 Months Ended					3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 17, 2020	Aug. 31, 2020	Feb. 29, 2020	Jan. 31, 2020	Aug. 31, 2019	Nov. 30, 2018	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Revenue								$ 11,565,000	$ 9,013,000	$ 20,859,000	$ 16,336,000
Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Receipt of upfront license fee			$ 9,500,000	$ 2,000,000.0			$ 1,750,000
Potential future payments based on achievement of development and regulatory milestones			6,000,000.0		$ 6,000,000.0					7,250,000
Potential future payments based on achievement of commercial-based milestones			6,000,000.0		$ 6,000,000.0					3,000,000.0
Development milestone payment received						$ 1,000,000.0
Potential future payments based on achievement of combined remaining development and sales milestone			11,750,000
Potential future payments based on achievement of remaining development and regulatory milestones			6,250,000
Potential future payments based on achievement of remaining commercial-based milestones			3,000,000.0
Ocumension Therapeutics [Member] | Share Offering [Member]
Disaggregation Of Revenue [Line Items]
Issuance of stock, net of issue costs, shares	3,010,722
Ocumension Therapeutics [Member] | Maximum [Member]
Disaggregation Of Revenue [Line Items]
Product supply milestones and development milestones										7,250,000
Upon achievement of milestones			$ 21,250,000
RPA [Member] | SWK [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment		$ 16,500,000
Revenue								198,000	181,000	423,000	361,000
Royalty payments								617,000	583,000	1,300,000	1,200,000
Royalty Sale Agreement [Member] | SWK [Member]
Disaggregation Of Revenue [Line Items]
Deferred revenue		$ 16,500,000
Deferred revenue, current								1,100,000		1,100,000		$ 1,100,000
Deferred revenue, non-current								14,100,000		14,100,000		$ 14,600,000
Product [Member]
Disaggregation Of Revenue [Line Items]
Revenue								11,318,000	8,738,000	20,328,000	15,540,000
Product [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue								11,000		67,000
License and Collaboration Revenue [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue								49,000	91,000	108,000	360,000
Collaborative Research and Development [Member]
Disaggregation Of Revenue [Line Items]
Revenue								$ 0	$ 0	$ 0	$ 60,000